Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 7/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309725 | 0.80 | ESR1 (0.52) | CYP3A4CYP11B2CYP17A1CYP11B1MPO | |
| SCHEMBL18850174 | 0.80 | GAA (0.50) | CYP3A4CYP11B2CYP17A1CYP11B1MPO | |
| SCHEMBL30437338 | 0.79 | MAPT (0.41) | MPOCYP26A1CYP24A1MIFELANE | |
| SCHEMBL18815830 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP11B2CYP17A1CYP11B1MPO | |
| SCHEMBL20211917 | 0.78 | ESR1 (0.46) | ESR1CYP26A1CYP24A1MIFHSD17B1 | |
| SCHEMBL29632065 | 0.78 | ESR1 (0.46) | ESR1CYP26A1CYP24A1MIFHSD17B1 | |
| SCHEMBL18845491 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP11B2CYP17A1CYP11B1ESR1 | |
| SCHEMBL28323713 | 0.77 | MPO (0.44) | MPOCYP26A1ELANE | |
| SCHEMBL31683684 | 0.77 | CYP3A4 (0.43) | CYP3A4CYP11B2CYP17A1CYP11B1MPO | |
| SCHEMBL19273758 | 0.77 | ELANE (0.44) | CYP3A4CYP11B2CYP17A1ESR1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274955-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-09-01 | — | — | US | claimed |
| EP-4699660-A2 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4021450-B1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2025-05-08 | — | — | US | disclosed |
| WO-2025090847-A1 | ESTROGEN RECEPTOR DEGRADERS AND THEIR USE IN THE TREATMENT OF CANCER | BPGBIO, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250120968-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12208095-B2 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3548483-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018144649-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas, Inc. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144649-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas, Inc. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CYP3A4 4541/4885CYP11B2 4416/4885CYP17A1 3213/4885 |
| US-12208095-B2 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | CYP3A4 116/4885CYP11B2 130/4885CYP17A1 80/4885 |
| US-20220274955-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CYP3A4 2896/4885CYP11B2 1588/4885CYP17A1 725/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CYP3A4 2896/4885CYP11B2 1588/4885CYP17A1 725/4885 |
| US-20250120968-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | CYP3A4 116/4885CYP11B2 130/4885CYP17A1 80/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CYP3A4 2896/4885CYP11B2 1588/4885CYP17A1 725/4885 |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | CD2BP2, CD47, EPCAM | CYP3A4 3352/4885CYP11B2 4324/4885CYP17A1 4755/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CYP3A4 4541/4885CYP11B2 4416/4885CYP17A1 3213/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | CYP3A4 4541/4885CYP11B2 4416/4885CYP17A1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.